Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Trulicity (dulaglutide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
• This summary is based on the review of 24 systematic review(s)/meta-analysis(es). ^[1-24]
• Dulaglutide, particularly at 1.5 mg, demonstrated significant reductions in HbA1c (-1.09%) in T2DM patients, with efficacy comparable or superior to other GLP-1RAs, including liraglutide, semaglutide, and exenatide.
• Dulaglutide induced a weight loss of -1.87 kg in T2DM patients, though this effect was less pronounced compared to semaglutide 1.0 mg (-5.99 kg) and tirzepatide.
• Dulaglutide showed a reduction in cardiovascular events, including nonfatal stroke and ischemic stroke, with efficacy comparable to other GLP-1RAs like semaglutide and liraglutide.
• Dulaglutide was particularly effective in reducing ischemic cerebrovascular events in T2DM patients with a shorter disease duration and higher baseline eGFR.
• Dulaglutide is associated with a higher incidence of gastrointestinal adverse effects, particularly nausea and vomiting, compared to placebo and other GLP-1RAs, but it does not significantly increase the risk of hypoglycemia.
• Dulaglutide may increase the risk of atrial fibrillation, though there is no significant increase in the risk of ventricular arrhythmias or sudden cardiac death; however, higher doses might increase the risk of ventricular arrhythmias in patients with higher baseline BMI.
• Gastrointestinal adverse events, such as pancreatitis, were the most frequently reported issues associated with dulaglutide.
• Dulaglutide has been found effective and safe in adults with Type 2 Diabetes Mellitus (T2DM), including those with advanced chronic kidney disease (CKD), end-stage kidney disease (ESKD), high cardiovascular risk, neuropsychiatric concerns, and high body mass index (BMI), showing significant improvements in blood glucose control, weight reduction, and cardiovascular outcomes.